Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2009

Giaccone Giuseppe, Rajan Arun, Ruijter Rita, Smit Egbert, van Groeningen Cees, Hogendoorn Pancras C W

Abstract excerpt

Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas. Anecdotal experience suggests activity of imatinib mesylate in TC. Patients with unresectable World Health Organization B3 thymomas or TC, performance status 0...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Imatinib Mesylate
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Thymoma

Share to Thymus Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 20197733
DOI: 10.1097/JTO.0b013e3181b6be57
PMCID: PMC7372705

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20197733-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.PMID 20197733Read ↗

Imatinib mesylate in thymic epithelial malignancies.Semantic proximity Read ↗

Expression and mutational status of c-kit in thymic epithelial tumors.Semantic proximity Read ↗

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.Semantic proximity Read ↗

Do thymic malignancies respond to target therapies?Semantic proximity Read ↗

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.Semantic proximity Read ↗

Absence of gene mutations in KIT-positive thymic epithelial tumors.Semantic proximity Read ↗

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.Semantic proximity Read ↗

C-KIT mutation in thymic carcinomas.Semantic proximity Read ↗

[Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].Semantic proximity Read ↗

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.Semantic proximity Read ↗

Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type of thymoma.Semantic proximity Read ↗

p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.